Pivotal Therapeutics Inc. Stock

Equities

PVTTF

CA72582E1043

Pharmaceuticals

Market Closed - OTC Markets 16:17:54 2023-03-23 EDT 5-day change 1st Jan Change
0.0018 USD +179,900.00% Intraday chart for Pivotal Therapeutics Inc. -.--% -.--%
Sales 2013 0.3 0.41 Sales 2014 0.31 0.42 Capitalization 5.56M 7.6M
Net income 2013 -2M -2.73M Net income 2014 -5M -6.83M EV / Sales 2013 54,242,447 x
Net Debt 2013 1.48M 2.03M Net Debt 2014 5.47M 7.47M EV / Sales 2014 35,969,990 x
P/E ratio 2013
-4.54 x
P/E ratio 2014
-1.03 x
Employees -
Yield 2013 *
-
Yield 2014
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Pivotal Therapeutics Inc. Announces Management Changes CI
Ford Teams with Pivotal to Speed Development of Connected Car Experiences Capitalizing on New Ford Sync Connect CI
Pivotal Therapeutics Inc. Executes International Distribution Agreement with Healthcore Co. Ltd CI
Pivotal Therapeutics Inc. Announces Earnings Results for the Nine Months Ended September 30, 2015 CI
Pivotal Therapeutics Inc. announced that it has received CAD 0.1 million in funding CI
Pivotal Therapeutics Inc. announced that it expects to receive CAD 1.58 million in funding CI
Pivotal Therapeutics Inc. Announces Financial Results for the Six Months Ended June 30, 2015 CI
Pivotal Therapeutics Inc. cancelled the transaction announced on June 29, 2015 CI
Pivotal Therapeutics Inc. announced that it expects to receive CAD 1.54 million in funding CI
Pivotal Therapeutics Inc. Announces the Enrollment of the First Patient in Pivotal's POMEGA Phase IIa Clinical Trial with PVT-100 CI
Pivotal Therapeutics Inc. Announces Audited Consolidated Earnings Results for the Three Months Ended March 31, 2015 CI
Pivotal Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2014 CI
Pivotal Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
Pivotal Therapeutics Inc. Receives Health Canada Approval to Expand the Indication of Omazen CI
Pivotal Therapeutics Inc. Executes Memorandum of Understanding for Distribution of Benefishial Line of Products in Korea CI
More news
3 years
0.00
Extreme 0
0.04
5 years
0.00
Extreme 0
0.16
10 years
0.00
Extreme 0
0.17
More quotes
Managers TitleAgeSince
Founder - 10-09-30
Founder - 10-09-30
Members of the board TitleAgeSince
Founder - 10-09-30
Chairman 77 11-11-21
Founder - 10-09-30
More insiders
Pivotal Therapeutics Inc is a Canada-based specialty pharmaceutical company with a focus on optimizing Omega-3 therapy for cardiovascular disease and overall health. The Company's lead product VASCAZEN is used to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase in high-density lipoprotein- Cholesterol (HDL-C) without a negative impact on the low density lipoprotein cholesterol (LDL-C) lipid profile. Its second product, OMAZEN is a greater than 90% pure, pharmaceutical grade Omega-3 commercialized for sale and distribution in Canada only for the maintenance of health.
More about the company